Betahydroxythiofentanyl
Clinical data
Other namesβ-hydroxythiofentanyl
ATC code
  • none
Legal status
Legal status
Identifiers
  • N-{1-[2-Hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl}-N-phenylpropanamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H26N2O2S
Molar mass358.50 g·mol−1
3D model (JSmol)
  • CCC(=O)N(c1ccccc1)C2CCN(CC2)CC(c3cccs3)O
  • InChI=1S/C20H26N2O2S/c1-2-20(24)22(16-7-4-3-5-8-16)17-10-12-21(13-11-17)15-18(23)19-9-6-14-25-19/h3-9,14,17-18,23H,2,10-13,15H2,1H3 checkY
  • Key:GLAAETOTOUGGSB-UHFFFAOYSA-N checkY
  (verify)

Betahydroxythiofentanyl (β-hydroxythiofentanyl) is an opioid analgesic that is an analog of fentanyl.

Betahydroxythiofentanyl was sold briefly on the black market from around 1985,[1] before the introduction of the Federal Analog Act in 1986 which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared.[2] β-hydroxythiofentanyl was anecdotally said to be one of the more favored fentanyl analogs by opiate addicts; however, its brief career as a street drug was short-lived and was eventually terminated with the introduction of the Federal Analogue Act.

Betahydroxythiofentanyl has similar effects to fentanyl. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[3]

As of October 2015, betahydroxythiofentanyl is a controlled substance in China.[4]

As of May 2016, betahydroxythiofentanyl is a Schedule I controlled substance in the United States.[5]

See also

References

  1. Valter K, Arrizabalaga P. Designer Drugs Directory (1998), p150. ISBN 0-444-20525-X
  2. Henderson GL (1988). "Designer Drugs: Past History and Future Prospects". Journal of Forensic Sciences. 33 (2): 569–575. doi:10.1520/JFS11976J. PMID 3286815.
  3. Mounteney J, Giraudon I, Denissov G, Griffiths P (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe". The International Journal on Drug Policy. 26 (7): 626–31. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.
  4. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
  5. "Schedules of Controlled Substances: Temporary Placement of Butyryl Fentanyl and Beta-Hydroxythiofentanyl into Schedule I" (PDF). Drug Enforcement Administration. 12 May 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.